Drugs / Gallium Ga 68-labeled PSMA-11
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04282824 | Jun 2019 → May 2020 | prostate carcinoma | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT04216134 | Dec 2019 → Dec 2022 | prostate carcinoma | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT05034562 | Sep 2022 | metastatic prostate carcinoma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03515577 | Apr 2019 | prostate carcinoma | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT04050215 | Apr 2018 → Sep 2021 | metastatic prostate carcinoma, prostate adenocarcinoma | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT03463889 | Mar 2018 → Sep 2020 | thyroid gland carcinoma | University of California, San Francisco | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Gallium Ga 68-labeled PSMA-11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04216134 ↗ |
| Known as | 68Ga-PSMA | “To determine the feasibility and utility of Gallium Ga 68-labeled PSMA-11 (68Ga-PSMA) PET imaging in patients with thyroid cancer.” NCT03463889 ↗ |
| Modality | Diagnostic / imaging agent | “Diagnostic procedures, such as 68Ga-PSMA PET, may more accurately diagnose thyroid cancer and find out how far the disease has spread.” NCT03463889 ↗ |
| Route | Intravenous | “Participants receive 68Ga-PSMA intravenously (IV) over 1-2 minutes” NCT03463889 ↗ |